Hypermarcas (OTCMKTS:HYPMY - Get Free Report) shares passed above its 50-day moving average during trading on Wednesday . The stock has a 50-day moving average of $4.13 and traded as high as $5.07. Hypermarcas shares last traded at $4.95, with a volume of 773,806 shares.
Hypermarcas Stock Performance
The stock has a market cap of $3.13 billion, a PE ratio of 20.60 and a beta of 0.79. The company has a quick ratio of 0.80, a current ratio of 1.26 and a debt-to-equity ratio of 0.63. The company has a fifty day moving average price of $4.13 and a 200 day moving average price of $3.53.
Hypermarcas (OTCMKTS:HYPMY - Get Free Report) last announced its quarterly earnings results on Wednesday, April 23rd. The company reported ($0.04) earnings per share (EPS) for the quarter. Hypermarcas had a net margin of 12.51% and a return on equity of 6.95%. The business had revenue of $184.34 million for the quarter.
About Hypermarcas
(
Get Free Report)
Hypera SA operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, please, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, moon, Lydian, macrodantin, Max Sulid, milgamma, Mioflex A, nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, Pressaliv, Quadriderm, Rizi, Rizi M, softalm, tacroz, tinodin, umma, and velunid brands.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Hypermarcas, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hypermarcas wasn't on the list.
While Hypermarcas currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for June 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
